Everything below concerns preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
For example, they are known to use both wine and raki in their ceremonial meetings, and were not known, in earlier times, to have observed the fast of Ramadan or the obligation of five daily prayer times. (ref: "Conforming Haji Bektash: A Saint and His Followers between Orthopraxy and Heteropraxy"; Mark Soileau, Die Welt des Islams 54 (2014) 423-459) Bektashis follow the modern-day Bektashi Dedebabate, currently headed by Baba Mondi. Bektashis consider the Dedebaba as leader over the entire branch. Bektashism is also heavily permeated with Shia Islamic concepts, such as the marked reverence of Ali, the Twelve Imams, and the ritual commemoration of Ashura marking the Battle of Karbala. The old Persian holiday of Nowruz is celebrated by Bektashis as Ali's birthday (see also Nevruz in Albania). The Bektashi order is a Sufi order and shares much in common with other Islamic mystical movements, such as the need for an experienced spiritual guide—called a baba in Bektashi parlance—as well as the Sufi doctrine of "the four gates that must be traversed": Sharī'a (religious law), Ṭarīqa (the spiritual path), Ma'rifa (true knowledge), and Ḥaqīqa (truth). There are many other practices and ceremonies that share similarities with other faiths, such as a ritual meal (muhabbet) and yearly confession of sins to a baba (magfirat-i zunub مغفرة الذنوب). Bektashis base their practices and rituals on their non-orthodox and mystical interpretation and understanding of the Quran and the prophetic practice (Sunnah).
Cushing also stated that Eddy was "a very interesting patient" who was "one of the most sensitive to the effects" of the morphine that he ever saw, and that to his surprise, the dose put her "sound asleep." Her husband Daniel Patterson was out of town at the time, but she was attended to by friends, Carrie Millett and Mary Wheeler, who took turns watching by her bedside. They told neighbors that Eddy had broken her back, was paralyzed, and possibly close to death; and at some point a call was made for a minister to come. After that Friday, Eddy apparently refused to take any more of his medicine, having lost her faith in homeopathy. On Sunday, February 4, she sent everyone out of the room and, according to her own account, she opened her Bible and read. She later wrote: "As I read, the healing Truth dawned upon my sense; and the result was that I rose, dressed myself, and ever after was in better health than I had before enjoyed." By eyewitness affidavit accounts, she then got out of bed, got dressed, and walked downstairs to the parlor to meet with her surprised and concerned friends who were gathered there with the minister. Eddy called this "the falling apple that led [her] to the discovery" of Christian Science, but she said that she did not understand it at first, and that she spent three years afterwards studying the Bible in order to understand better how she had been healed. Although Cushing had not visited Eddy on that Sunday, on Monday Cushing visited her again to check up.
=== 1. CAL vs. Pseudopocket === Clinical attachment loss refers to the loss of periodontal attachment due to apical migration of the junctional epithelium (JE), accompanied by destruction of gingival connective tissue fibers and periodontal ligament fibers. This results in the formation of a true periodontal pocket, where the base of the pocket lies apical to the cementoenamel junction (CEJ). CAL develops through a complex host–microbial interaction, beginning with microbial dysbiosis, commonly involving anaerobic pathogens such as Porphyromonas gingivalis. This dysbiotic biofilm triggers an exaggerated host immune response, characterized by neutrophil infiltration, pro-inflammatory cytokine release, and complement activation. With chronic inflammation, destructive enzymes such as matrix metalloproteinases are activated, leading to the breakdown of gingival connective tissue fibers and detachment from the cementum. This allows the JE to migrate apically, deepening the periodontal pocket and facilitating further bacterial invasion. Simultaneously, inflammatory mediators stimulate RANKL-mediated osteoclast activation, resulting in alveolar bone resorption. Biologically, this process is irreversible, involving permanent breakdown of the JE, connective tissue fibers, periodontal ligament, and supporting bone. Clinically, CAL is the gold standard for diagnosing periodontitis and marks the transition from gingivitis to established periodontal disease. In contrast, a pseudopocket is characterized by increased probing depth without attachment loss.
For non-isotropic stresses in rigid bodies, depending on how the orientation of a surface is chosen, the same distribution of forces may have a component of positive stress along one surface normal, with a component of negative stress acting along another surface normal. The pressure is then defined as the average of the three principal stresses. The stresses in an electromagnetic field are generally non-isotropic, with the stress normal to one surface element (the normal stress) being negative, and positive for surface elements perpendicular to this. In cosmology, dark energy creates a very small yet cosmically significant amount of negative pressure, which accelerates the expansion of the universe.
== Founding fathers of the United States == John Jay (King's 1764), president of the Continental Congress; first chief justice of the United States; author of five of The Federalist papers; first secretary of foreign affairs under the Articles of Confederation; architect of Jay Treaty with Great Britain Robert Livingston (King's 1764), a writer of the Declaration of Independence as part of the Committee of Five; first U.S. secretary of foreign affairs; negotiator of the Louisiana Purchase Egbert Benson (King's 1765), delegate to the Continental Congress, U.S. representative, first New York State attorney general, chief justice of the New York Supreme Court Gouverneur Morris (King's 1768), represented Pennsylvania in the Continental Congress; authored much of the United States Constitution; U.S. ambassador to France; United States senator from New York Alexander Hamilton* (King's 1776), American Revolutionary War officer, aide-de-camp to George Washington; most prolific writer of The Federalist Papers; first United States secretary of the treasury, portrayed on the ten-dollar bill; founder of the Bank of New York
Sources: en.wikipedia.org
The board included members with relevant biomedical expertise such as past president of the American Association for Clinical Chemistry Susan A. Evans; William Foege, former director of the U.S. Centers for Disease Control and Prevention (CDC); David Helfet, director of the Orthopedic Trauma Service at the Hospital for Special Surgery; and professors Ann M. Gronowski, Larry J. Kricka, Jack Ladenson, Andy O. Miller and Steven Spitalnik. Balwani left his position as president and COO in May 2016. At that time, the company announced its new board members, Fabrizio Bonanni (former executive vice president of Amgen), Richard Kovacevich and William Foege, who would help to publicly introduce its technologies. In May 2016, members of the Theranos board of directors were:
However, since opioid antagonists also block the beneficial effects of opioid analgesics, they are generally useful only for treating overdose, with use of opioid antagonists alongside opioid analgesics to reduce side effects, requiring careful dose titration and often being poorly effective at doses low enough to allow analgesia to be maintained. Naltrexone does not appear to increase risk of serious adverse events, which confirms the safety of oral naltrexone. Mortality or serious adverse events due to rebound toxicity in patients with naloxone were rare.
=== Enterohepatic circulation === Research by Aarons has focused on enterohepatic cycling (EHC) which refers to the process whereby a drug goes through the liver and biliary tract for excretion and is released into the small intestine, where it can be reabsorbed back into circulation and subsequently returned to the liver. This can cause liver damage and the half-life and duration of a drug to be increased. Aarons and his team stressed that knowing the extent of EHC is invaluable in deciding whether or not the in vitro characteristics of a drug - i.e. those taking place outside of a living organism - will have any effect on the overall process of absorption in vivo, or when it is taking place inside the organism. Aarons had earlier been involved in research on the area under the curve (AUC). This is a pharmacokinetic statistic used to describe the total exposure to a drug - specifically the concentration of a drug in body fluids such as blood - and is useful because it gives insight into the extent of exposure to a drug and its clearance rate from the body. The research was seen as important in the "design of sampling protocols for accurate determination of AUC(0– ∞) for drugs subject to enterohepatic cycling."
Confirming a diagnosis of carotid artery stenosis is important because the treatment for this condition, carotid endarterectomy, can pose significant risk to the patient, including heart attacks and strokes after the procedure. For this reason, the U.S. Preventive Services Task Force (USPSTF) "recommends against screening for asymptomatic carotid artery stenosis in the general adult population". This recommendation is for asymptomatic patients, so it does not necessarily apply to patients with TIAs as these may in fact be a symptom of underlying carotid artery disease (see "Causes and Pathogenesis" above). Therefore, patients who have had a TIA may opt to have a discussion with their clinician about the risks and benefits of screening for carotid artery stenosis, including the risks of surgical treatment of this condition. Cardiac imaging can be performed if head and neck imaging do not reveal a vascular cause for the patient's TIA (such as atherosclerosis of the carotid artery or other major vessels of the head and neck). Echocardiography can be performed to identify patent foramen ovale (PFO), valvular stenosis, and atherosclerosis of the aortic arch that could be sources of clots causing TIAs, with transesophageal echocardiography being more sensitive than transthoracic echocardiography in identifying these lesions.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.